Signal Genetics Inc Stock Nasdaq
Stocks
US8266401046
Biotechnology & Medical Research
|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| 09-16 | Sling Therapeutics raises $123 million to advance thyroid eye disease drug | RE |
| 08-31 | Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push | RE |
| Market Cap | 2.27B 2B 1.89B 1.72B 3.22B 217B 3.25B 22.69B 8.75B 111B 8.51B 8.32B 357B | P/E 2026 * |
-5.06x | P/E 2027 * | -7.81x |
|---|---|---|---|---|---|
| Enterprise Value | 1.48B 1.3B 1.23B 1.12B 2.1B 142B 2.12B 14.81B 5.71B 72.43B 5.55B 5.43B 233B | EV / Sales 2026 * |
49.2x | EV / Sales 2027 * | 7.54x |
| Free-Float |
99.32% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Signal Genetics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Stephen Mahoney
CEO | Chief Executive Officer | 55 | 2023-10-29 |
Seth Harmon
DFI | Director of Finance/CFO | 46 | 2023-09-11 |
Kirk Bertelsen
CTO | Chief Tech/Sci/R&D Officer | - | 2023-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Arlene Morris
BRD | Director/Board Member | 74 | 2018-01-02 |
Tomas Kiselak
CHM | Chairman | 40 | 2021-05-31 |
Jennifer Moses
BRD | Director/Board Member | 51 | 2021-07-13 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.16% | -0.30% | +58.96% | +94.17% | 71.53B | |
| -0.19% | +1.32% | +37.20% | +81.33% | 60.12B | |
| -1.51% | +2.39% | +9.10% | +36.79% | 48.85B | |
| +0.84% | +1.22% | +42.74% | +39.84% | 44.28B | |
| +1.27% | +9.09% | +345.55% | +695.07% | 43.83B | |
| +1.88% | +2.36% | +9.66% | +109.31% | 41.53B | |
| -0.67% | -0.45% | +4.47% | +46.37% | 30.13B | |
| +4.77% | +6.46% | +41.54% | +22.78% | 27.98B | |
| -0.32% | -2.30% | -19.71% | +355.74% | 25.25B | |
| Average | +1.19% | +0.48% | +58.84% | +164.60% | 43.72B | |
| Weighted average by Cap. | +1.29% | +0.63% | +63.88% | +155.55% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 30.04M 26.51M 25.09M 22.75M 42.65M 2.88B 43.07M 301M 116M 1.47B 113M 110M 4.74B | 234M 206M 195M 177M 332M 22.45B 335M 2.34B 903M 11.46B 879M 859M 36.89B |
| Net income | -464M -410M -387M -351M -659M -44.53B -665M -4.65B -1.79B -22.74B -1.74B -1.7B -73.18B | -320M -282M -267M -242M -454M -30.68B -458M -3.2B -1.23B -15.67B -1.2B -1.17B -50.42B |
| Net Debt | -787M -695M -657M -596M -1.12B -75.53B -1.13B -7.88B -3.04B -38.57B -2.96B -2.89B -124B | -501M -442M -419M -380M -712M -48.1B -719M -5.02B -1.94B -24.56B -1.88B -1.84B -79.04B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
